
    
      This study had three sequential parts which investigated the safety and tolerability of
      VAY736 administered as single ascending doses of intravenous infusion (Part 1), single
      ascending doses of subcutaneous injection (Part 2), and repeated subcutaneous injections of
      fixed doses (Part 3), respectively, in rheumatoid arthritis patients. Part 1 was double
      blind, placebo controlled, with 11 cohorts. Part 2 was open-label study with 2 dosing
      cohorts. Part 3 was open-label study with 1 fixed-dose cohort.
    
  